Five Prime Therapeutics (FPRX) Tops Q4 EPS by 7c

Five Prime Therapeutics (NASDAQ: FPRX) reported Q4 EPS of ($0.89), $0.07 better than the analyst estimate of ($0.96). Revenue for the quarter came in at $3.2 million versus the consensus estimate of $4.65 million.

“Our 2020 focus is on generating clinical data from three proprietary programs that will allow us to prioritize future pipeline investments,” said William Ringo, interim Chief Executive Officer and Chairman of the Board. “Additionally, we are advancing our novel late-stage research programs and plan to bring one new program into preclinical development later this year. We are also looking to acquire early-stage clinical assets that we can develop to generate actionable data in the near- to medium-term by utilizing our clinical development and translational expertise.”

For earnings history and earnings-related data on Five Prime Therapeutics (FPRX) click here.

You May Also Be Interested In

• Capital One beats Q2 EPS by $1.13 as Discover integration gains pace
• Calidi Biotherapeutics (CLDI) Reports Q2 Loss of $2.94
• Workhorse Group (WKHS) Misses Q2 EPS by 77c